Eli Lilly’s CDK4/6 inhibitor Verzenio significantly extended overall survival in the monarchE trial among patients with hormone receptor-positive, HER2-negative early breast cancer with high recurrence risk. These findings, marking a secondary endpoint, complement earlier data on invasive disease-free survival leading to initial approval. Verzenio is established as a standard-of-care option in this subtype, enhancing long-term outcomes while maintaining a consistent safety profile. Data will be presented at upcoming conferences.